Physician profile
Sumedha Dhar
NPI 1811204266
$2,097.44
in general payments reported to CMS, 2019-2025
14 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.15 · 2020: $87.10 · 2021: $85.00 · 2022: $208 · 2023: $82.43 · 2024: $843 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582 · Education: $37.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.18 |
| Education | $37.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.10 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $229.95 | 2024-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $225.04 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $200.51 | 2024-2025 | |
| Amgen INC. | $161.15 | 2024-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $152.47 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $125.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $122.80 | 2024 | Inpefa |
| Vifor Pharma, INC. | $114.10 | 2022-2023 | Veltassa |
| Biosense Webster, INC. | $87.10 | 2020 | |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Scpharmaceuticals INC. | $40.95 | 2025 | |
| Fresenius USA Marketing, INC. | $33.28 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumedha Dhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.